This firm's average rating is Buy from 6 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Biodelivery Sci market sentiment investors' perception of the future value of Biodelivery. Let us look at a few aspects of Biodelivery technical analysis.
How important is BioDelivery Sciences's Liquidity
BioDelivery Sciences
financial leverage refers to using borrowed capital as a funding source to finance BioDelivery Sciences International ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. BioDelivery Sciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to BioDelivery Sciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of BioDelivery Sciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between BioDelivery Sciences's total debt and its cash.
Another Deeper Perspective
The company has a beta of -0.3807. Let's try to break down what Biodelivery's beta means in this case. As returns on the market increase, Biodelivery Sci returns are expected to increase less than the market. However, during the bear market, the loss on holding Biodelivery Sci will be expected to be smaller as well. The beta indicator helps investors understand whether Biodelivery Sci moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Biodelivery deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
The current Biodelivery Sci Intl price drop could raise concerns from stockholders as the firm it trading at a share price of
3.36 on very low momentum in volume. The company executives were unable to exploit market volatilities in
December. However, diversifying your overall positions with Biodelivery Sci Intl can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.47. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Biodelivery Sci partners.
Will Biodelivery Sci current rise continue?
Current mean deviation is at 2.23. Biodelivery Sci Intl exhibits very low volatility with skewness of 3.34 and kurtosis of 23.75. However, we advise investors to further study Biodelivery Sci Intl technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biodelivery Sci's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biodelivery Sci's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Biodelivery Sci Implied Volatility
Biodelivery Sci's implied volatility exposes the market's sentiment of Biodelivery Sci Intl stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biodelivery Sci's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biodelivery Sci stock will not fluctuate a lot when Biodelivery Sci's options are near their expiration.
Our Conclusion on Biodelivery Sci
While some companies under the drug manufacturers—specialty & generic industry are still a bit expensive, Biodelivery Sci may offer a potential longer-term growth to stockholders. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Biodelivery as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biodelivery Sci.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of BioDelivery Sciences International. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
